2 gene editing biotechs team up to improve on delivery with $45 upfront

The gene-editing scene is heating up with the big players rising to the top, see Intellia, CRISPR Therapeutics and more. Now, two small biotechs are going to try and up their game together in a research deal worth $45 million.

Myeloid Therapeutics and Prime Medicine have signed an exclusive option and research collaboration to develop Myeloid’s RNA-based gene-editing technology, dubbed “RetroT." Prime is shelling out $45 million upfront for the opportunity.